Nexien BioPharma, Inc. Announces Resignation of Alain Bankier as Executive Chair of the Board and Chief Strategy Officer
April 03, 2019 at 10:20 pm
Share
Nexien BioPharma, Inc. announced that on April 1, 2019, Alain Bankier, who had been serving as the registrant’s Executive Chair of the Board and Chief Strategy Officer resigned from all positions due to personal reasons. He had also been serving on the Audit Committee of the Board of Directors. Mr. Bankier will continue to serve in an advisory capacity.
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
NEXIEN BIOPHARMA, INC. 
